<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the ADAMTS13 antigen levels and activity in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>) and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> (AIS), and explore its significance in these diseases </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: ADAMTS13 activity levels were detected by a new developed Frests-vWF73 kit, ADAMTS13 antigen levels by ELISA kit, and vWF multimers by electrophoresis </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: ADAMTS13 antigen in <z:mpath ids='MPATH_458'>normal</z:mpath> control, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> and AIS was (878 +/- 198), (618 +/- 188) and (702 +/- 155) U/L, and ADAMTS13 activity was (81.7 +/- 13.9)%, (59.2 +/- 22.1 )% and (65.4 +/- 15.8)%, respectively, being significantly decreased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> and AIS patients </plain></SENT>
<SENT sid="3" pm="."><plain>CONCLUSION: ADMATS13 might involve in arterial infarction diseases </plain></SENT>
</text></document>